1h Free Analyst Time
SummarySpeak directly to the analyst to clarify any post sales queries you may have.
The latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H2 2020, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.
Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 5, 13, 18, 1, 25, 17 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.
Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
- Introduction
- Chronic Kidney Disease - Overview
- Chronic Kidney Disease - Therapeutics Development
- Chronic Kidney Disease - Therapeutics Assessment
- Chronic Kidney Disease - Companies Involved in Therapeutics Development
- Chronic Kidney Disease - Drug Profiles
- Chronic Kidney Disease - Dormant Projects
- Chronic Kidney Disease - Discontinued Products
- Chronic Kidney Disease - Product Development Milestones
- Appendix
List of Tables
- Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Products under Development by Companies, H2 2020
- Products under Development by Universities/Institutes, H2 2020
- Number of Products by Stage and Target, H2 2020
- Number of Products by Stage and Mechanism of Action, H2 2020
- Number of Products by Stage and Route of Administration, H2 2020
- Number of Products by Stage and Molecule Type, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algernon Pharmaceuticals Inc, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algomedix Inc, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Annji Pharmaceutical Co Ltd, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aronora Inc, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics Inc, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim International GmbH, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cadila Healthcare Ltd, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H2 2020
- Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H2 2020
List of Figures
- Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H2 2020
- Number of Products under Development by Companies, H2 2020
- Number of Products under Development by Universities/Institutes, H2 2020
- Number of Products by Top 10 Targets, H2 2020
- Number of Products by Stage and Top 10 Targets, H2 2020
- Number of Products by Top 10 Mechanism of Actions, H2 2020
- Number of Products by Stage and Top 10 Mechanism of Actions, H2 2020
- Number of Products by Top 10 Routes of Administration, H2 2020
- Number of Products by Stage and Top 10 Routes of Administration, H2 2020
- Number of Products by Top 10 Molecule Types, H2 2020
- Number of Products by Stage and Top 10 Molecule Types, H2 2020
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Algernon Pharmaceuticals Inc
- Algomedix Inc
- Allena Pharmaceuticals Inc
- Angion Biomedica Corp
- Annji Pharmaceutical Co Ltd
- apceth Biopharma GmbH
- Arch Biopartners Inc
- Aronora Inc
- AstraZeneca Plc
- Bayer AG
- BioAegis Therapeutics Inc
- Boehringer Ingelheim International GmbH
- Boryung Pharmaceutical Co Ltd
- Cadila Healthcare Ltd
- Cellmid Ltd
- Cinkate Corp
- Corvidia Therapeutics Inc
- Daiichi Sankyo Co Ltd
- DiaMedica Therapeutics Inc
- Dimerix Ltd
- Dizal (Jiangsu) Pharmaceutical Co Ltd
- DJS Antibodies Ltd
- DURECT Corp
- Evotec SE
- G3 Pharmaceuticals Inc
- GNI Group Ltd
- Icagen Inc
- Immunitor Inc
- Indalo Therapeutics Inc (Inactive)
- INVENT Pharmaceuticals Inc
- ITB-Med AB
- Kaleido Biosciences Inc
- KBP BioSciences Co Ltd
- KidneyCure Ltd
- Kintai Therapeutics Inc
- Klotho Therapeutics Inc
- Lignamed LLC
- Liminal BioSciences Inc
- Merck & Co Inc
- Meridigen Biotech Co Ltd
- Novartis AG
- Novo Nordisk AS
- OPKO Health Inc
- Opsidio LLC
- OrthoTrophix Inc
- ProKidney LLC
- Reata Pharmaceuticals Inc
- Redx Pharma Plc
- Rege Nephro Co Ltd
- Reliance Life Sciences Pvt Ltd
- Renibus Therapeutics Inc
- Resverlogix Corp
- Sarfez Pharmaceuticals Inc
- Scohia Pharma Inc
- Senolytic Therapeutics Inc
- Sentien Biotechnologies Inc
- Sphaera Pharma Pte Ltd
- TagCyx Biotechnologies
- Unicocell Biomed Co Ltd
- Unity Biotechnology Inc
- Vascular BioSciences
- VESSL Therapeutics Ltd
- Vidasym Inc
